1308 related articles for article (PubMed ID: 31880140)
1. [Cell therapy's poster child: Chimeric antigen receptor T cell therapy].
Qian L; Chen J; Wu X; Jing R; Sun J
Sheng Wu Gong Cheng Xue Bao; 2019 Dec; 35(12):2339-2349. PubMed ID: 31880140
[TBL] [Abstract][Full Text] [Related]
2. Ophthalmic Implications of Chimeric Antigen Receptor T-Cell Therapy.
Chodnicki KD; Prasad S
Semin Ophthalmol; 2021 May; 36(4):329-334. PubMed ID: 33689570
[TBL] [Abstract][Full Text] [Related]
3. Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility.
Celichowski P; Turi M; Charvátová S; Radhakrishnan D; Feizi N; Chyra Z; Šimíček M; Jelínek T; Bago JR; Hájek R; Hrdinka M
J Transl Med; 2023 Mar; 21(1):197. PubMed ID: 36922828
[TBL] [Abstract][Full Text] [Related]
4. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
5. Chimeric antigen receptor-engineered T-cell therapy for liver cancer.
Chen Y; E CY; Gong ZW; Liu S; Wang ZX; Yang YS; Zhang XW
Hepatobiliary Pancreat Dis Int; 2018 Aug; 17(4):301-309. PubMed ID: 29861325
[TBL] [Abstract][Full Text] [Related]
6. [Progression in chimeric antigen receptor T (CAR-T) cell therapy of solid tumors: A review].
Fang Z; Han H; Liang L
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2019 Oct; 35(10):944-948. PubMed ID: 31814572
[TBL] [Abstract][Full Text] [Related]
7. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy.
Schubert ML; Schmitt M; Wang L; Ramos CA; Jordan K; Müller-Tidow C; Dreger P
Ann Oncol; 2021 Jan; 32(1):34-48. PubMed ID: 33098993
[TBL] [Abstract][Full Text] [Related]
8. Preclinical Models in Chimeric Antigen Receptor-Engineered T-Cell Therapy.
Siegler EL; Wang P
Hum Gene Ther; 2018 May; 29(5):534-546. PubMed ID: 29390873
[TBL] [Abstract][Full Text] [Related]
9. Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances.
Zhang T; Tai Z; Miao F; Zhang X; Li J; Zhu Q; Wei H; Chen Z
J Control Release; 2024 Apr; 368():372-396. PubMed ID: 38408567
[TBL] [Abstract][Full Text] [Related]
10. Strategies to overcome the side effects of chimeric antigen receptor T cell therapy.
Mirzaee Godarzee M; Mahmud Hussen B; Razmara E; Hakak-Zargar B; Mohajerani F; Dabiri H; Fatih Rasul M; Ghazimoradi MH; Babashah S; Sadeghizadeh M
Ann N Y Acad Sci; 2022 Apr; 1510(1):18-35. PubMed ID: 34982476
[TBL] [Abstract][Full Text] [Related]
11. A review of chimeric antigen receptor T-cells in lymphoma.
Anderson JK; Mehta A
Expert Rev Hematol; 2019 Jul; 12(7):551-561. PubMed ID: 31177852
[No Abstract] [Full Text] [Related]
12. [Chimeric antigen receptor T cell (CAR-T) therapy for refractory/relapsed hematological malignancy].
Hiramatsu H
Rinsho Ketsueki; 2018; 59(10):1948-1954. PubMed ID: 30305496
[TBL] [Abstract][Full Text] [Related]
13. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
Front Immunol; 2018; 9():1717. PubMed ID: 30108584
[TBL] [Abstract][Full Text] [Related]
14. Chimeric Antigen Receptor T-Cell Therapy: Current Perspective on T Cell-Intrinsic, T Cell-Extrinsic, and Therapeutic Limitations.
Brookens SK; Posey AD
Cancer J; 2023 Jan-Feb 01; 29(1):28-33. PubMed ID: 36693155
[TBL] [Abstract][Full Text] [Related]
15. CAR-T cell and Personalized Medicine.
Cruz-Ramos M; García-Foncillas J
Adv Exp Med Biol; 2019; 1168():131-145. PubMed ID: 31713169
[TBL] [Abstract][Full Text] [Related]
16. Combining the best of two worlds: highly flexible chimeric antigen receptor adaptor molecules (CAR-adaptors) for the recruitment of chimeric antigen receptor T cells.
Darowski D; Kobold S; Jost C; Klein C
MAbs; 2019; 11(4):621-631. PubMed ID: 30892136
[TBL] [Abstract][Full Text] [Related]
17. Cytokine release syndrome was an independent risk factor associated with hypoalbuminemia for patients with relapsed/refractory hematological malignancies after CAR-T cell therapy.
Ding S; Chen R; Wang L; Zu C; Zhou X; Zhang J; Zhang M; Jin A; Wang T; Hu Y
BMC Cancer; 2023 Nov; 23(1):1055. PubMed ID: 37919691
[TBL] [Abstract][Full Text] [Related]
18. Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy.
Ti D; Niu Y; Wu Z; Fu X; Han W
Sci China Life Sci; 2018 Nov; 61(11):1320-1332. PubMed ID: 30414005
[TBL] [Abstract][Full Text] [Related]
19. Challenges and Prospects of Chimeric Antigen Receptor T-cell Therapy for Metastatic Prostate Cancer.
Gorchakov AA; Kulemzin SV; Kochneva GV; Taranin AV
Eur Urol; 2020 Mar; 77(3):299-308. PubMed ID: 31471138
[TBL] [Abstract][Full Text] [Related]
20. Current Challenges in Chimeric Antigen Receptor T-cell Therapy in Patients With B-cell Lymphoid Malignancies.
Kim SJ; Yoon SE; Kim WS
Ann Lab Med; 2024 May; 44(3):210-221. PubMed ID: 38205527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]